Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;6(4):437-447.
doi: 10.1001/jamacardio.2020.7073.

Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women

Affiliations

Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women

Sagar B Dugani et al. JAMA Cardiol. .

Abstract

Importance: Risk profiles for premature coronary heart disease (CHD) are unclear.

Objective: To examine baseline risk profiles for incident CHD in women by age at onset.

Design, setting, and participants: A prospective cohort of US female health professionals participating in the Women's Health Study was conducted; median follow-up was 21.4 years. Participants included 28 024 women aged 45 years or older without known cardiovascular disease. Baseline profiles were obtained from April 30, 1993, to January 24, 1996, and analyses were conducted from October 1, 2017, to October 1, 2020.

Exposures: More than 50 clinical, lipid, inflammatory, and metabolic risk factors and biomarkers.

Main outcomes and measures: Four age groups were examined (<55, 55 to <65, 65 to <75, and ≥75 years) for CHD onset, and adjusted hazard ratios (aHRs) were calculated using stratified Cox proportional hazard regression models with age as the time scale and adjusting for clinical factors. Women contributed to different age groups over time.

Results: Of the clinical factors in the women, diabetes had the highest aHR for CHD onset at any age, ranging from 10.71 (95% CI, 5.57-20.60) at CHD onset in those younger than 55 years to 3.47 (95% CI, 2.47-4.87) at CHD onset in those 75 years or older. Risks that were also noted for CHD onset in participants younger than 55 years included metabolic syndrome (aHR, 6.09; 95% CI, 3.60-10.29), hypertension (aHR, 4.58; 95% CI, 2.76-7.60), obesity (aHR, 4.33; 95% CI, 2.31-8.11), and smoking (aHR, 3.92; 95% CI, 2.32-6.63). Myocardial infarction in a parent before age 60 years was associated with 1.5- to 2-fold risk of CHD in participants up to age 75 years. From approximately 50 biomarkers, lipoprotein insulin resistance had the highest standardized aHR: 6.40 (95% CI, 3.14-13.06) for CHD onset in women younger than 55 years, attenuating with age. In comparison, weaker but significant associations with CHD in women younger than 55 years were noted (per SD increment) for low-density lipoprotein cholesterol (aHR, 1.38; 95% CI, 1.10-1.74), non-high-density lipoprotein cholesterol (aHR, 1.67; 95% CI, 1.36-2.04), apolipoprotein B (aHR, 1.89; 95% CI, 1.52-2.35), triglycerides (aHR, 2.14; 95% CI, 1.72-2.67), and inflammatory biomarkers (1.2- to 1.8-fold)-all attenuating with age. Some biomarkers had similar CHD age associations (eg, physical inactivity, lipoprotein[a], total high-density lipoprotein particles), while a few had no association with CHD onset at any age. Most risk factors and biomarkers had associations that attenuated with increasing age at onset.

Conclusions and relevance: In this cohort study, diabetes and insulin resistance, in addition to hypertension, obesity, and smoking, appeared to be the strongest risk factors for premature onset of CHD. Most risk factors had attenuated relative rates at older ages.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ridker reported receiving grants from the National Heart, Lung, and Blood Institute, Amarin, Kowa, and Novartis, and personal fees from Agepha, Amarin, Bayer, CivibioPharm, Corvidia, Iqvia, Inflazome, Jansson, and Sanofi outside the submitted work. Dr Ridker is listed as a coinventor on patents held by the Brigham and Women's Hospital related to the use of inflammatory biomarkers in cardiovascular disease (licensed to AstraZeneca and Siemens). Dr Glynn reported receiving research grants to the Brigham & Women’s Hospital from AstraZeneca, Kowa, Novartis, and Pfizer. Dr Mora reported receiving institutional research grant support from Atherotech Diagnostics for research outside the current work, served as a consultant to Quest Diagnostics, and has a patent regarding the use of GlycA in relation to colorectal cancer risk. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Associations of Clinical Risk Factors and Lipid Biomarkers per SD Increment With Incident Coronary Heart Disease (CHD) by Age at CHD Onset
Hazard ratios (95% CI) were obtained from stratified Cox proportional hazards regression models (stratified by age groups and blood draw time categories) adjusted for model 1 covariates (baseline race/ethnicity, educational level categories, menopause, postmenopausal hormone use, randomized treatment assignment, and interactions between the risk factor of interest and age groups). Hazard ratios were based on the presence vs absence of risk factors. Hazard ratios and 95% CIs are provided in Table 2, and SDs are provided in eTable 1 in the Supplement. BMI indicates body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and MI, myocardial infarction.
Figure 2.
Figure 2.. Associations of Lipoprotein Particles per SD Increment With Incident Coronary Heart Disease (CHD) by Age at CHD Onset for Low-Density Lipoprotein (LDL) Particles, Triglyceride-Rich Lipoprotein (TRL) Particles, and High-Density Lipoprotein (HDL) Particles
Hazard ratios (95% CI) were obtained from stratified Cox proportional hazards regression models (stratified by age groups and blood draw time categories) adjusted for model 1 covariates (baseline race/ethnicity, educational level categories, menopause, postmenopausal hormone use, randomized treatment assignment, and interactions between the risk factor of interest and age groups). To further adjust for confounding among LDL subclasses, their models included model 1 covariates plus the other LDL subclasses (large, medium, or small LDL particles). To adjust for confounding between total LDL particles and LDL particle average size, their models included model 1 covariates plus the other LDL biomarkers (total LDL particles or LDL particle average size).
Figure 3.
Figure 3.. Associations of Inflammatory and Metabolic Biomarkers per SD Increment With Incident Coronary Heart Disease (CHD) by Age at CHD Onset
Hazard ratios (95% CI) were obtained from stratified Cox proportional hazards regression models (stratified by age groups and blood draw time categories) adjusted for model 1 covariates (baseline race/ethnicity, educational level categories, menopause, postmenopausal hormone use, randomized treatment assignment, and interactions between the risk factor of interest and age groups). Hazard ratios were based on the presence vs absence of risk factors. BCAAs indicates branched chain amino acids; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GlycA, glycan biomarker of N-acetyl side chains of several acute-phase proteins; ICAM-1, intercellular adhesion molecule 1; and LPIR, lipoprotein insulin resistance.

Similar articles

Cited by

References

    1. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369(14):1336-1343. doi:10.1056/NEJMra1109345 - DOI - PubMed
    1. De Sutter J, De Bacquer D, Kotseva K, et al. ; EUROpean Action on Secondary Prevention through Intervention to Reduce Events II study group . Screening of family members of patients with premature coronary heart disease; results from the EUROASPIRE II family survey. Eur Heart J. 2003;24(3):249-257. doi:10.1016/S0195-668X(02)00386-X - DOI - PubMed
    1. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group . EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-137. doi:10.1097/HJR.0b013e3283294b1d - DOI - PubMed
    1. Lloyd-Jones DM, Nam B-H, D’Agostino RB Sr, et al. . Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204-2211. doi:10.1001/jama.291.18.2204 - DOI - PubMed
    1. Wilmot KA, O’Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart disease mortality declines in the United States from 1979 through 2011. Circulation. 2015;132(11):997-1002. doi:10.1161/CIRCULATIONAHA.115.015293 - DOI - PMC - PubMed

Publication types

MeSH terms